Skip to main content

Biomedicines: extraordinary opportunities amidst uncertain times

Published on September 30, 2026   38 min

A selection of talks on Pharmaceutical Sciences

Please wait while the transcript is being prepared...
0:00
Hello. My name is Michael Kinch. I'm the chief innovation officer at Stonybrook University on Long Island in New York in the United States. Today, we're going to be talking about biomedicines, extraordinary opportunities amidst uncertain times.
0:17
The pharmaceutical industry is arguably the most regulated industry on the planet. This regulation is a logical extension of many different rules and laws that have come into place to avoid unsafe or ineffective medicines. The consequence, as shown in the slide, is that, you'll notice what would occur in the early 20th century which medicines that were targeting consumers with products that were potentially safe or ineffective. In this case, it's an advertisement for tapeworms to be used for weight loss which is very unsafe, and while effective, the effectiveness ends when the patient ends up being killed or seriously harmed by the treatment. We've gone from that situation to the modern situation which is shown on the right part of the slide. What it refers to is a congressional testimony in 2011 by an executive from Eli Lilly & Company pointed out that if you were to print out all of the different pages if it were required to gain approval for a drug called Efient, that particular product approval would be taller than the Empire state building. Clearly we've reached a situation where we've gone from no regulation to arguably over regulation or at a minimum, very heavy regulation. Why is this the case? Where do we go from here? Now, if we look at

Quiz available with full talk access. Request Free Trial or Login.

Show
Hide

Biomedicines: extraordinary opportunities amidst uncertain times

Embed in course/own notes